The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goulet, J. L.
Right arrow Articles by Koller, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goulet, J. L.
Right arrow Articles by Koller, B. H.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*INDOMETHACIN
The Journal of Immunology, 2000, 164: 4899-4907.
Copyright © 2000 by The American Association of Immunologists

Genetic Factors Determine the Contribution of Leukotrienes to Acute Inflammatory Responses1

Jennifer L. Goulet*,{dagger}, Robert S. Byrum*, Mikelle L. Key*, MyTrang Nguyen*, Victoria A. Wagoner* and Beverly H. Koller2,*

* Department of Medicine, University of North Carolina, Chapel Hill, NC 27599; and {dagger} Division of Nephrology, Department of Medicine, Duke University and Durham Veterans Affairs Medical Centers, Durham, NC 27705


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Leukotrienes (LT) are potent lipid mediators synthesized by the 5-lipoxygenase pathway of arachidonic acid (AA) metabolism. LT have been implicated in a broad spectrum of inflammatory processes. To investigate the influence of genetic factors on the contribution of LT to acute inflammation, we generated congenic 5-lipoxygenase-deficient 129, C57BL/6 (B6), and DBA/1Lac (DBA) mouse lines. Topical application of AA evoked a vigorous inflammatory response in 129 and DBA mice, whereas only a modest response was seen in B6 animals. The response to AA in 129 and DBA strains is LT dependent. In contrast, LT make little contribution to this response in B6 mice. AA-induced inflammation in B6 mice is prostanoid dependent, since this response was substantially reduced by treating B6 mice with a cyclooxygenase inhibitor. These data suggest that prostanoids are essential for AA-induced cutaneous inflammation in B6 mice, whereas LT are the major mediators of this response in 129 and DBA strains. In contrast, the response to AA in the peritoneal cavity is robust in the 129 and B6 strains, but was significantly blunted in DBA mice, showing that strain differences in the response to AA are tissue specific. Variations in these and other experimental models of inflammation appear to correlate directly with the ability of a particular mouse strain and a specific tissue to respond to LT, specifically LTC4. Taken together, these findings indicate that the relative contribution of prostanoids and LT to inflammatory responses is variable not only between strains but also between different tissues within these inbred mouse lines.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Leukotrienes (LT)3 are products of the 5-lipoxygenase (5LO) pathway of arachidonic acid (AA) metabolism. LT belong to a family of AA-derived molecules, termed eicosanoids, which also include the cyclooxygenase (COX) pathway products, the prostanoids (1, 2, 3). The first step in the biosynthesis of these lipid mediators is the release of AA from endogenous phospholipids by one of several phospholipases (PL), particularly cytosolic PLA2, which occurs following stimulation, infection, or injury (4, 5, 6). Free AA is then sequestered at the nuclear envelope and brought into contact with the 5LO enzyme by an accessory protein termed the 5-lipoxygenase-activating protein, which facilitates the conversion of AA by 5LO to the unstable intermediate LTA4 (7, 8, 9, 10). LTA4 can then be either converted to LTB4 by the action of LTA4 hydrolase or conjugated with glutathione by LTC4 synthase to produce the first of the cysteinyl-LT, LTC4, and its metabolites LTD4 and LTE4 (11, 12).

LT can elicit many of the physiological events associated with inflammation, including edema formation, vasopermeability, and cellular infiltration (2, 11, 12, 13). LTB4 is the most potent natural chemoattractant for neutrophils, eosinophils, and monocytes (14, 15, 16). In addition, it has been shown that LTB4 stimulates adhesion of leukocytes to vascular endothelia for extravasation into adjacent tissue (12, 17). LTB4 also initiates neutrophil aggregation and degranulation (12). The cDNA encoding the LTB4 receptor (B-LT receptor) has been cloned recently and, as predicted by pharmacological studies, this receptor is a seven-membrane-spanning G-protein-coupled receptor (18). Studies have shown that the B-LT receptor is highly expressed in peripheral blood leukocytes and, to a lesser degree, in spleen and thymus. However, its expression is limited since most other tissues examined showed no or insignificant expression of mRNA for the B-LT receptor (18). Activation of B-LT receptors results in mobilization of Ca2+, accumulation of inositol trisphosphate, and inhibition of adenylyl cyclase (18).

Although cysteinyl-LT do not directly stimulate migration of leukocytes to inflammatory lesions, they play an important role in edema formation during the inflammatory response. LTC4 and its metabolites, LTD4 and LTE4, are secreted in vivo by eosinophils, mast cells, and macrophages (12, 13). These mediators act directly on the microvasculature by inducing vasoconstriction and increasing postcapillary venule permeability, thereby allowing leakage of fluid and proteins and facilitating migration of leukocytes into the inflammatory site (12, 13, 17). The cysteinyl-LT mediate their activities through at least two distinct receptors termed Cys-LT1 (formerly the "LTD4 receptor") and Cys-LT2 (formerly the "LTC4 receptor") (19, 20). The recent cloning of Cys-LT1 indicates that this receptor, unlike the B-LT receptor, has a broad tissue distribution, including peripheral blood leukocytes, spleen, and lung, suggesting that LTC4 could influence the function of many cell types (21).

A direct means of determining the contribution of LT to an inflammatory response was made available by the generation of mouse lines deficient in either the 5LO enzyme or the 5-lipoxygenase-activating protein (22, 23, 24, 25). Using these mouse lines, we and others have defined a role for LT in several models of acute inflammation (22, 23, 24). However, these studies revealed variability in both the intensity of inflammatory responses in wild-type mice and the extent to which loss of LT production affected these responses. We suspected that these differences were linked to the fact that both 5LO-deficient mice and wild-type controls were F2 generation animals, containing a mixture of genes from the 129/Ola-derived embryonic stem (ES) cells and the B6D2F1 (F1 offspring of C57BL/6 x DBA/2 crosses) animals to which chimeras were bred. Therefore, we set out to determine whether modifier genes altered the magnitude of inflammatory responses and also to determine the contribution of LT to these processes.

The influence of genetic background on immunological processes in mice, although poorly understood in most instances, has been recognized since the development of inbred mouse strains. In recent years, it has become apparent that genetic differences between strains of mice can result in qualitative and quantitative differences in immune responses. For example, it is now well accepted that T cell responses are dominated by Th2-type cells in the BALB/c mouse, whereas the Th1 cell is prevalent in immune responses in the C57BL/6 (B6) mouse. Studies have also shown significant variability in the airway responsiveness phenotype of various inbred mouse strains (26). In addition, the multiple intestinal neoplasia (Min) mouse, a model for human familial adenomatous polyposis, demonstrates the modification of disease by genetic background. Min mice differ greatly in the number of intestinal tumors, depending on the mouse strain carrying this mutation (27, 28). Recently, studies have shown that the gene encoding the group II secretory nonpancreatic PLA2 (sPLA2) enzyme is naturally disrupted in a number of inbred mouse strains and has been identified as a candidate gene for the modifier of the Min 1 (Mom1) locus (27, 28). Loss of sPla2 gene function results in susceptibility to the Min phenotype and the formation of multiple intestinal polyps, whereas mice expressing an active sPla2 gene are resistant to polyp formation. The mouse strains B6 and 129/Sv were found to be homozygous for the defective sPla2 gene, whereas DBA/1 and DBA/2 mice had a normal sPla2 genotype at this locus (27, 28).

The ability to generate mice that carry a null allele for proteins involved in the synthesis of inflammatory mediators, and the subsequent generation of congenic mouse lines carrying the null allele, makes it possible to identify a role for modifier genes in specific inflammatory responses. To investigate the effect of genetic factors on the contribution of LT to acute inflammation, we generated three congenic lines of 5LO-deficient mice. The disrupted 5lo allele was maintained on a relatively inbred 129 genetic background and was also backcrossed onto several other inbred strains, including B6 and DBA/1Lac (DBA). Although no differences were seen in the general health or development of these three mouse lines, significant variations in the contribution of LT to AA-induced ear inflammation and peritonitis were observed. Moreover, the relative contribution of modifier genes to AA-induced inflammatory responses were shown to be tissue specific. We also demonstrated that the variation in the intensity of inflammation between strains results primarily from differences in the ability of a particular mouse strain and a specific tissue to respond to LTC4.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Mice

Chimeric animals were created by microinjecting 5lo-targeted embryonic stem cells derived from the 129/Ola mouse strain into B6 host blastocysts (23). The 5lo mutation was maintained on a relatively inbred 129 genetic background by breeding chimeras with 129/SvEv mice. Inbred B6 mice homozygous for the mutant 5lo allele were generated by backcrossing the 5lo mutation onto the B6 mouse strain for 12 generations and then intercrossing the resulting N12 B6-5lo+/- mice. 5LO-deficient DBA mice were created by repeatedly backcrossing animals heterozygous for the targeted 5lo gene mutation to DBA mice for a minimum of eight generations. Intercrosses of DBA mice heterozygous for the disrupted 5lo allele produced DBA-5lo-/- and DBA-5lo+/+ animals. 129/SvEv, B6, and DBA mice used for breeding were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were screened for the 5lo mutation by Southern blot analysis of EcoRI-digested tail genomic DNA as described previously (23). All mice studied were at least 8 wk old and were bred and maintained in specific pathogen-free animal barrier facilities at the University of North Carolina.

Induction of inflammatory responses in mouse ear tissue

Animals were injected i.v. with either 0.5% Evans blue dye (Sigma, St. Louis, MO) dissolved in PBS (pH 7.5; 10 ml of dye solution/kg body wt) or with indomethacin (INDO; 1 mg/ml in 0.1 M Na2CO3 and 0.15 M Na2HPO4, pH 7.4; Sigma) combined with 0.5% Evans blue dye (10 mg INDO/kg body weight). The inside of the left ear of each mouse was painted with 20 µl of AA (100 µg/µl in acetone; Sigma), while the right ear was treated with an equal amount of acetone alone. In related experiments, the left ear of each mouse was injected intradermally with either 5 µl of LTC4 (20 ng/µl in 1:4 ethanol:PBS; Cayman Chemicals, Ann Arbor, MI) or 20 µl of PGE1 (Cayman Chemicals) combined with bradykinin (BK; Sigma; 25 ng/µl in 1:19 ethanol:PBS). As a control, the right ear was injected with equal amounts of vehicle alone. At 1 h after AA or LTC4 treatment, or 30 min after PGE1 plus BK intradermal injections, mice were sacrificed and an 8-mm-diameter disc of tissue was punched from the center of each ear.

Edema and vascular permeability measurements in mouse ear tissue

Edema was measured by determining the wet weight of the ear punches. To extract extravasated Evans blue dye, ear biopsies were incubated in 1 ml of formamide at 55°C for 48 h. Evans blue was quantified by measuring the absorbance of the formamide extracts at 610 nm with a spectrophotometer (29).

Induction of peritoneal inflammation

For the zymosan A peritonitis experiments, inflammation was induced using a modification of the procedure of Rao et al. (30). Zymosan A (Sigma) was dissolved in warm (55°C) PBS to a final concentration of 1 mg/ml and mixed until it passed freely through a 30-gauge syringe needle. Mice were injected i.p. with 1 ml of zymosan A solution. In related experiments, mice received i.p. injections of 0.5 ml of either LTC4 (100 ng in 1:499 ethanol:PBS), AA (2 mg in 1:24 acetone:PBS), PGE1 plus BK (1 µg of each in 1:249 ethanol:PBS), or equal volumes of vehicle alone. All mice received i.v. injections of 0.5% Evans blue dye solution immediately before administration of inflammatory stimuli.

Quantification of edema and vascular permeability in peritonitis inflammatory models

Thirty minutes after zymosan A or LTC4 i.p. injections, or 1 h after AA or PGE1 plus BK administration, mice were euthanized and injected i.p. with 4 ml of PBS. The abdomen was massaged for a few seconds to mix its contents, and lavage fluids were collected into polypropylene tubes on ice through a small incision. Samples that were visibly red and therefore contaminated with blood were not included in analyses. Lavage fluid (1 ml) was centrifuged at 40,000 x g for 10 min and supernatants were collected. The extravasation of Evans blue dye in the lavage fluid was quantified by spectrophotometric analysis (610 nm wavelength).

Statistical analysis

Data are presented as the mean ± SEM. Statistical significance for comparisons between groups was determined using an unpaired two-sample t test.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Generation and characterization of 5LO-deficient congenic mouse lines

To generate 5LO-deficient mouse lines, chimeras created by injection of 5lo-targeted ES cells into B6 host blastocysts (23) were bred to either 129/SvEv, B6, or DBA mice. The parental ES cell line, E14TG2a (31), from which the 5lo-targeted line was generated, was derived from the 129/Ola mouse strain and therefore the 5lo mutation could be maintained on a relatively inbred 129 genetic background by breeding chimeras with 129/SvEv mice. B6 and DBA mice congenic for the 5lo mutation were generated by repeatedly crossing 5lo heterozygotes to B6 and DBA mice for 12 generations. Intercrosses between B6 and DBA mice that were heterozygous for the 5lo mutation produced wild-type (5lo+/+) B6 and 5LO-deficient (5lo-/-) B6 mice and DBA-5lo+/+ and DBA-5lo-/- animals. No differences were seen in the growth and development, survival, and overall health of mice deficient in 5LO on any of the three genetic backgrounds.

AA-induced inflammation in ears of 129, B6, and DBA wild-type mice

Previous studies using F2 generation mice of a mixed background consisting of genes from 129, B6, and DBA mouse strains showed large animal to animal variation in the intensity of the inflammatory responses to topically applied AA (23). To determine whether this variation reflected differences in the ability of the three strains to respond to AA, we examined the effect of this stimulus on the ear tissue of 129, B6, and DBA wild-type inbred mice. Inflammation was measured by determining both the change in weight of an ear biopsy and the extravasation of plasma protein. Protein extravasation was assayed by injecting the mice with Evans blue, a dye which binds to serum proteins, before the administration of AA and quantifying the amount of dye in the ear tissue. As shown in Fig. 1Go, topical application of AA resulted in a significant increase in edema and vascular permeability, as measured by changes in ear weight and plasma protein extravasation, respectively, in treated tissue of both 129 and DBA inbred mice. The intensity of the AA-induced inflammatory responses was similar in wild-type mice of 129 and DBA strains (Fig. 1Go, p = 0.225 and p = 0.331, respectively). In contrast, only a modest increase in ear weight in response to AA was observed in inbred B6-5lo+/+ mice. AA-stimulated edema in this group was significantly less than that seen in both 129- and DBA-5lo+/+ animals (Fig. 1GoA, p = 2.65 x 10-7 and 8.05 x 10-7, respectively). A corresponding difference in the amount of protein extravasation in B6-5lo+/+ mice compared with both wild-type 129 and DBA animals was also noted (Fig. 1GoB, p = 3.09 x 10-7 and 0.00015, respectively). These data demonstrate that the vascular response of inbred wild-type B6 mice to AA is significantly less vigorous than the response seen in either wild-type 129 or DBA inbred mouse strains.



View larger version (33K):
[in this window]
[in a new window]
 
FIGURE 1. AA-induced acute inflammatory responses in wild-type and congenic 5LO-deficient mouse lines. Edema and vascular permeability changes were assessed for 129-, B6-, and DBA-5lo+/+ and 5lo-/- mice. Before the application of 2 mg of AA in acetone to the left ear and acetone alone to the right ear, mice received an i.v. injection of 0.5% Evans blue dye solution. After 1 h, mice were sacrificed, 8-mm-diameter discs of tissue were taken from each ear, and the difference in weight between the right ear and left ear for each animal was recorded (A). The extravasation of dye into the tissue was then quantitated by extraction of dye with formamide and measurement of absorbance at a wavelength of 610 nm. For each animal, the A610 obtained for the right ear was subtracted from that obtained for the left ear (B). Error bars indicate SEM. n, Number of mice in each group.

 
AA-induced inflammation in 5LO-deficient inbred mice

Using 5LO-deficient mice of a mixed genetic background, we and others have shown that LT play an important role in AA-induced inflammatory responses (22, 23). These studies also indicated that, while loss of 5LO decreased the edema and vascular permeability elicited by AA, a residual LT-insensitive response remained in the 5LO-deficient animals. To determine whether the variation in this inflammatory model among the 129, B6, and DBA strains reflects differences in this LT-independent response or in the role of LT in these three mouse strains, we compared the effect of topically applied AA on ear tissue of wild-type 129, B6, and DBA mice to that of congenic animals deficient in 5LO.

A significant reduction in AA-induced edema and vascular permeability, as measured by increases in ear weight and extravasation of serum proteins, was seen in the inbred 129-5lo-/- animals compared with 129 wild-type mice (Fig. 1Go, p = 1.61 x 10-13 and 1.68 x 10-12, respectively). Loss of 5LO activity also significantly reduced these responses in inbred DBA mice (Fig. 1Go, p = 5.97 x 10-6 and 1.87 x 10-5, respectively). The 5lo mutation on each of these two genetic backgrounds resulted in a significant attenuation of AA-stimulated acute inflammation compared with wild-type counterparts. However, the AA-induced increase in ear weight was slightly lower in 129-5lo-/- mice than in DBA-5lo-/- animals (Fig. 1GoA, p = 0.005). Serum protein extravasation, as determined by the amount of dye in the ear tissue, was reduced to a similar level in both 129-5lo-/- and DBA-5lo-/- animals (Fig. 1GoB, p = 0.119). In both strains, however, the loss of 5LO did not completely eliminate the inflammatory response to AA.

In contrast to the decreased inflammatory responses to AA in the 5LO-deficient 129 and DBA mice, the loss of 5LO had no impact on the inflammatory response elicited by AA in the B6 mouse strain. 5LO deficiency strongly inhibited AA-induced ear inflammation in the 129 (76–77%) and DBA (59–69%) strains, but had no effect on these responses in B6 (-3 to -5%) animals (Table IGo). Alterations in ear weight and dye extravasation in response to AA were similar in wild-type and 5LO-deficient B6 mice (Fig. 1Go, p = 0.423 and 0.375, respectively). AA-induced edema, as measured by ear weight increases, was higher in B6-5lo-/- mice than in 129- and DBA-5lo-/- animals (Fig. 1GoA, p = 3.45 x 10-5 and 0.183, respectively). Also, protein extravasation in B6-5lo-/- mice was significantly increased compared with 5LO-deficient mice of both the 129 and DBA strains (Fig. 1GoB, p = 0.00019 and 0.0295, respectively). Taken together, these data clearly show that the loss of 5LO activity significantly reduced AA-induced inflammation in the ears of 129 and DBA mice, but had no effect on this response in the B6 strain.


View this table:
[in this window]
[in a new window]
 
Table I. Effect of 5lo mutation on AA-induced ear inflammation

 
Effects of indomethacin on AA-induced edema in 5lo+/+ and 5lo-/- mice

We showed previously that the AA-induced inflammatory response remaining in 5LO-deficient mice of a mixed genetic background is sensitive to the COX inhibitor INDO (23). Therefore, we determined whether the LT-independent inflammatory response seen in the B6 mice also results from the synthesis of prostanoids, the products of the COX pathways, by treating wild-type and 5LO-deficient 129, B6, and DBA mice with INDO before the application of AA. As can be seen in Fig. 2GoA, AA-induced edema was slightly lower in INDO-treated 129 wild-type mice than in untreated 129 mice, but this difference was not significant (p = 0.294 and Table IIGo). The amount of dye extravasation was also comparable in INDO-treated and untreated wild-type mice of the 129 strain (Fig. 2GoB, p = 0.056, and Table IIGo). Similarly, inhibition of the COX pathway by treatment with INDO had no effect on AA-induced inflammation, measured by either ear weight or dye extravasation, in wild-type DBA mice (Fig. 2Go, p = 0.295 and 0.196, respectively, and Table IIGo).



View larger version (36K):
[in this window]
[in a new window]
 
FIGURE 2. Inhibition of AA-induced acute inflammation by INDO. For each mouse, the left ear was treated with 2 mg of AA in acetone and the right ear was treated with vehicle alone. Mice received an i.v. injection of either 0.5% Evans blue dye solution or 0.5% Evans blue plus INDO (10 mg/kg). After 1 h, mice were sacrificed, 8-mm-diameter discs of tissue were taken from each ear, and the difference in weight between the right ear and left ear for each animal was recorded (A). The extravasation of dye into the tissue was then quantitated by extraction of dye with formamide and measurement of absorbance at a wavelength of 610 nm. For each animal, the A610 obtained for the right ear was subtracted from that obtained for the left ear (B). Error bars indicate SEM. n, Number of mice in each group.

 

View this table:
[in this window]
[in a new window]
 
Table II. Inhibition of AA-induced ear inflammation by INDO

 
In contrast, INDO treatment led to significant decreases in edema (67%) (Fig. 2GoA, p = 0.0013) and vascular permeability (49%) (Fig. 2GoB, p = 0.029) in 129–5LO-deficient mice (Table IIGo). However, these responses were only reduced by 20–25% by INDO in DBA-5lo-/- mice (Fig. 2Go, p = 0.104 and 0.207, respectively, and Table IIGo). These data suggest that prostanoids contribute to the residual AA-induced inflammation in 5LO-deficient 129 and DBA mouse lines, although the relative role of these lipid mediators in this model is dependent on the genetic background of the mice being studied.

The inflammatory response seen in B6 mice is significantly reduced by treatment of the mice with INDO before application of AA, regardless of 5LO activity. As shown in Table IIGo, edema and vascular permeability were inhibited by 69 and 38%, respectively, in B6 wild-type mice and, moreover, these responses were greatly reduced (73–77%) by INDO in B6-5lo-/- animals. These data indicate that the vascular component of the AA inflammatory model in the B6 mouse strain is dependent primarily on prostanoid synthesis.

LTC4-induced cutaneous inflammation in wild-type inbred mouse strains

We examined the possibility that the differential role of LT in the inflammatory models described above reflects variation in the ability of mouse strains to respond to LT. To test this hypothesis, we studied the effect of exogenously administered LTC4 on edema formation and vascular permeability in ear tissue of high- and low-responding mouse strains. After labeling serum proteins with i.v. Evans blue, as described above, we injected LTC4 intradermally in the left ear of B6 and 129 wild-type mice. As seen in Fig. 3Go, LTC4 was effective in causing both edema and increased vascular permeability, as measured by increases in ear weight and dye extravasation, respectively, in 129 mice. In contrast to the responses of 129 mice, only small increases in edema and vasopermeability were observed in ear biopsies from B6 wild-type mice after exposure to LTC4 (Fig. 3Go, p = 0.0008 and 0.0115, respectively).



View larger version (30K):
[in this window]
[in a new window]
 
FIGURE 3. Acute inflammatory responses in ear tissue of wild-type 129 and B6 inbred mouse strains. Mice received an i.v. injection of 0.5% Evans blue dye solution immediately before the intradermal injection of either 100 ng of LTC4 or 500 ng of PGE1 + BK in the left ear and vehicle alone in the right ear. At 1 h after LTC4 treatment or 30 min after PGE1 + BK intradermal injections, mice were sacrificed and an 8-mm-diameter disc of tissue was taken from each ear. The difference in weight between the right ear and left ear for each animal was recorded (A). The extravasation of dye into the tissue was then quantitated by extraction of dye with formamide and measurement of absorbance at a wavelength of 610 nm. For each animal, the A610 obtained for the right ear was subtracted from that obtained for the left ear (B). Error bars indicate SEM. n, Number of mice in each group.

 
To show that the variation in responses to LTC4 was specific to this inflammatory stimulus and not due to differences in anatomy or physiology between these strains, we examined the effect of another acute, exogenously administered, inflammatory stimulus, PGE1 in combination with BK, on edema formation and vascular permeability in the ear tissue of wild-type 129 and B6 mice. As shown in Fig. 3Go, intradermal injections of PGE1 plus BK resulted in significant increases in both edema and vascular permeability in ear biopsies of 129 and B6 mice. However, the intensity of inflammation induced by this stimulus was similar in the 129 and B6 mouse strains (Fig. 3Go, p = 0.151 and 0.140, respectively), suggesting that gross physiological differences between the two strains do not account for the variation observed in the cutaneous response to LTC4.

AA-induced inflammatory responses in the peritoneal cavities of 5lo+/+ and 5lo-/- mice

To determine whether the variation in these inflammatory responses between mouse strains is specific to cutaneous tissue, we also examined the effect of i.p. administration of AA in 129, B6, and DBA mice. Animals were injected i.v. with Evans blue, and the levels of this dye in lavage fluid after AA challenge were quantitated as a measurement of vascular permeability in the peritoneal cavity. Baseline levels of Evans blue dye extravasation in lavage fluids from wild-type and 5LO-deficient mice injected i.p. with PBS were not significantly different among the three strains (data not shown). Therefore, only data for wild-type mice treated with PBS are shown in Fig. 4Go. AA treatment resulted in increased dye extravasation in all three mouse strains. However, the vascular response of DBA-5lo+/+ mice was significantly lower than that seen in the 129 (Fig. 4Go, p = 0.0002) and B6 (Fig. 4Go, p = 0.053) wild-type mouse strains. Although a greater increase in vascular permeability was seen in the B6 wild-type mice compared with the DBA strain, this level of inflammation was significantly lower than that observed in 129 mice (Fig. 4Go, p = 0.0163). These results are contrary to those of the experiments described above, in which the response of B6 mice to topically applied AA was significantly lower than that of both 129 and DBA mouse strains.



View larger version (26K):
[in this window]
[in a new window]
 
FIGURE 4. AA-induced peritoneal inflammation. Mice received 0.5% Evans blue dye solution i.v. immediately before AA (2 mg) or PBS i.p. injection. After 1 h, mice were sacrificed and the peritoneal cavity was lavaged with 4 ml of PBS. Cells were removed by centrifugation and the extravasation of Evans blue dye in lavage fluids was then quantitated by spectrophotometric analysis (610 nm wavelength). There were no significant differences between the responses of wild-type and 5LO-deficient mice that were treated with PBS. Therefore, only data for PBS-treated 5lo+/+ mice are shown. Error bars indicate SEM. n, Number of mice in each group.

 
To determine the role of LT in AA-induced increases in vascular permeability, we compared the effect of i.p. administration of AA in wild-type 129, B6, and DBA mice to that of congenic animals deficient in 5LO. As can be seen in Fig. 4Go, we observed a significant decrease in Evans blue dye extravasation in the inbred 129-5lo-/- mice compared with 129-5lo+/+ animals (p = 0.0008). This response was also significantly reduced in 5LO-deficient B6 mice (Fig. 4Go, p = 0.0195). In contrast, the 5lo mutation had no effect on AA-induced inflammation in the DBA mouse strain (Fig. 4Go, p = 0.450). The loss of 5LO activity significantly inhibited AA-induced peritonitis in the 129 (22%) and B6 (14%) mouse strains, but had no impact on this inflammatory response in the DBA mice (-1.3%, Table IIIGo). The increased levels of plasma protein extravasation stimulated by AA were not significantly different (p > 0.05) among the three 5LO-deficient mouse lines, suggesting that the 5LO-independent component of this response is similar in the 129, B6, and DBA mouse strains.


View this table:
[in this window]
[in a new window]
 
Table III. Effect of the 5lo mutation on AA-induced peritonitis

 
Zymosan A-induced peritonitis in 5lo+/+ and 5lo-/- mice

To determine whether the strain differences observed in the responses to AA extended to other inflammatory responses, we examined zymosan A-induced peritonitis in wild-type and 5lo-/- 129, B6, and DBA animals. We have shown previously, using the inbred 129–5LO-deficient mice, that plasma protein extravasation induced by zymosan A is almost completely dependent on the production of LT by 5LO during the early phases of the response (24). As can be seen in Fig. 5Go, we observed a significant decrease in zymosan A-stimulated inflammation, as measured by Evans blue dye extravasation, in the inbred 129-5lo-/- mice (p = 3.23 x 10-12). The increase in dye extravasation elicited by zymosan A was of similar magnitude in the B6-5lo+/+ mice compared with 129 wild-type animals (Fig. 5Go, p = 0.135) and a corresponding large decrease in this response was seen in the B6-5lo-/- animals compared with the wild-type B6 mice (Fig. 5Go, p = 0.00011). Zymosan A administration also resulted in an increase in dye extravasation in DBA-5lo+/+ mice, although the intensity of the response was significantly lower than that seen in the 129 and B6 wild-type mouse strains (Fig. 5Go, p = 1.27 x 10-6 and 0.00043, respectively). Although zymosan A-induced inflammation was significantly inhibited by 34% in the DBA-5lo-/- animals (Fig. 5Go, p = 0.0375), this percent reduction was less than that observed in the 129 (72%) and B6 (67%) mice (Table IVGo).



View larger version (24K):
[in this window]
[in a new window]
 
FIGURE 5. Zymosan A-induced peritoneal inflammation in wild-type and congenic 5LO-deficient mouse lines. Mice received 0.5% Evans blue dye solution i.v. immediately before zymosan A (1 mg) i.p. injection. After 30 min, mice were sacrificed and the peritoneal cavity was lavaged with 4 ml of PBS. Cells were removed by centrifugation and the extravasation of Evans blue dye in lavage fluids was then quantitated by spectrophotometric analysis (610 nm wavelength). Error bars indicate SEM. n, Number of mice in each group.

 

View this table:
[in this window]
[in a new window]
 
Table IV. Effect of the 5lo mutation on zymosan A-induced peritonitis

 
LTC4-induced peritoneal inflammation in wild-type inbred mouse strains

We next determined whether the responses of the 129 and DBA mouse strains to i.p. administration of LTC4 correlated with the effects of other inflammatory stimuli, such as AA and zymosan A, in this tissue. As seen in Fig. 6Go, treatment with LTC4 resulted in a significant increase in vascular permeability, as measured by Evans blue dye extravasation, in the peritoneal cavities of 129 wild-type mice. These data are consistent with those described above (Figs. 4Go and 5Go), in which a vigorous response is seen in 129 mice after i.p. administration of either AA or zymosan A. In contrast, the vascular response of DBA mice after exposure to LTC4 was significantly less vigorous than the response to LTC4 observed in the 129 strain (Fig. 6Go, p = 0.0165). As a control, 129 and DBA mice were injected i.p. with PGE1 plus BK, and the resulting alterations in vascular permeability were similar in the DBA and 129 wild-type animals (Fig. 6Go, p = 0.406).



View larger version (25K):
[in this window]
[in a new window]
 
FIGURE 6. Peritoneal inflammation in wild-type 129 and DBA mouse strains. Mice received an i.v. injection of 0.5% Evans blue dye solution before i.p. injections of either 100 ng of LTC4 or 1 µg of PGE1 + BK. Thirty min after LTC4 injections or 1 h after PGE1 + BK administration, mice were sacrificed and the peritoneal cavity was lavaged with 4 ml of PBS. Cells were removed by centrifugation and the extravasation of Evans blue dye in lavage fluids was then quantitated by spectrophotometric analysis (610 nm wavelength). Error bars indicate SEM. n, Number of mice in each group.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Previous experiments have shown large animal to animal variation in the responses of both wild-type and 5LO-deficient mice of a mixed genetic background to various inflammatory stimuli. In this study, we investigated the influence of genetic factors on the role of LT in acute inflammation by generating congenic 5LO-deficient mouse lines on three inbred strains: 129, B6, and DBA. We show that both wild-type and 5LO-deficient mouse strains differ in their responsiveness to several stimuli, including AA and zymosan A, and that the variation in each of these experimental models of inflammation correlates directly with the ability of a particular mouse strain and a specific tissue to respond to LT, specifically LTC4. Table VGo presents an overall summary of differences among the three mouse strains in the various inflammatory responses described above.


View this table:
[in this window]
[in a new window]
 
Table V. Comparative analysis of strain effects in various acute inflammatory models

 
Topical application of AA evoked a robust inflammatory response in both 129 and DBA mice, whereas only a modest response was seen in B6 wild-type animals. Examination of this response in congenic mouse lines that are deficient in the 5LO enzyme allowed the isolation of the LT-mediated component of this model. The intensity of AA-induced ear inflammation was similar in B6-5lo+/+ and B6-5lo-/- animals; in contrast, this response was substantially blunted in 5LO-deficient mice on the 129 and DBA strains. It is clear from these experiments that genetic factors determine the ability of AA to induce inflammation in the ear tissue of inbred wild-type mice and that genetic factors also determine the specific contribution of LT to these inflammatory processes.

Although LT appear to be the major mediators of AA-induced acute inflammation, it has been demonstrated that prostanoids produced via the COX pathways also play a role in this model (23, 32, 33, 34, 35, 36). Treatment of wild-type mice with the COX inhibitor INDO allowed us to examine the contribution of prostanoids to AA-induced cutaneous inflammation. Treatment of 5LO-deficient mice with INDO in this model allowed us to explore the potential shunting of AA between the 5LO and COX pathways in different mouse strains. Analysis of the AA-induced response in 129, B6, and DBA mice indicated differences among all three strains in the various pathways that contribute to this response. The level of inflammation induced by AA in 129 and DBA wild-type mice is similar and in both strains the response is largely mediated by LT, with only a small LT-independent component. The response to AA in wild-type mice of these two strains is largely unaffected by treatment with INDO, suggesting that prostanoids normally make only a minor contribution to the vascular component of this inflammatory model. However, consistent with our previous studies, the experiments described here show that prostanoids have a more significant effect on the inflammatory response to AA in the 5LO-deficient 129 and DBA mice than in their wild-type counterparts, suggesting that tissues in these strains may compensate for the loss of 5LO in part by altering the synthesis and/or activity of prostanoids to modulate the inflammatory response. Moreover, INDO pretreatment had a greater influence on the residual AA-induced inflammation in the 5LO-deficient 129 strain than in DBA-5lo-/- mice. These data suggest that edema and increased vasopermeability result largely from the actions of prostanoids in 129 mice that are deficient in 5LO and, therefore, unable to synthesize LT. In contrast, the AA-induced cutaneous response seen in the DBA-5LO-deficient mice is largely INDO insensitive. Presumably, residual inflammation in ear tissue of INDO-treated DBA-5lo-/- mice results from unidentified mediators that are generated independent of the expression of either 5LO or prostaglandin synthase enzymes. Therefore, prostanoids may not be able to initiate inflammation independent of other mediators in the DBA strain. Alternatively, it is possible that shunting of AA to the COX pathways is less efficient in the DBA strain.

In comparison to the responses of 129 and DBA mice, edema and changes in vascular permeability evoked by AA were attenuated in the B6 wild-type mice. Moreover, this response was largely 5LO independent and thus remains virtually identical to that observed in the B6–5LO-deficient animals. The response induced by topical application of AA in both wild-type and 5LO-deficient mice of the B6 strain is almost entirely prostanoid dependent.

Taken together, these results indicate that mouse strains can differ substantially in the relative contribution of LT to inflammatory responses and in the ability of prostanoids to induce inflammation in the absence of LT. These data suggest that the relative roles of LT and prostanoids and additional 5LO- and/or prostanoid-independent inflammatory mediators in this acute inflammatory response are strongly influenced by genetic background.

It is also evident that the effects of genetic factors on inflammatory processes depend upon the specific tissue being examined. The AA peritonitis model allowed us to determine whether genetic modifiers affect LT-sensitive responses elicited by the same inflammatory stimuli in different tissues. Significant interstrain variation is apparent in the response to AA injected into the peritoneal cavity of wild-type inbred mice. However, the 5lo mutation had no effect on AA-induced peritoneal inflammation in DBA mice, whereas LT play a major role in AA-induced cutaneous inflammation in this mouse strain. In contrast, as discussed above, the 5LO pathway does not contribute measurably to the response to topical AA in the B6 mouse strain. However, a significant difference in plasma protein extravasation was observed between wild-type and 5LO-deficient B6 mice in response to administration of AA into the peritoneal cavity. Our data demonstrated that a mouse strain which shows little or no response to AA when it is applied topically may react very strongly when a different tissue is exposed to the same stimulus. To determine whether the genetic background of the mouse would play a role in other inflammatory responses, we examined zymosan A-induced peritonitis in the same inbred mouse lines. A vigorous LT-dependent inflammatory response to zymosan A was seen in the B6 mouse and it was similar in magnitude to that of 129 wild-type animals. In contrast, inflammation in the peritoneal cavities of DBA mice was significantly blunted in response to both AA and zymosan A and had only a minor LT-sensitive component.

Interstrain differences in the contribution of LT to an inflammatory response could reflect alterations in the activity of the 5LO pathway and subsequent synthesis and metabolism of LT and/or in the response of a specific tissue to LT. We addressed these possibilities by treating wild-type inbred mice with exogenous LTC4. We found that the variation observed in other experimental models of inflammation correlates directly with the ability of a particular mouse strain and a specific tissue to respond to cysteinyl-LT, specifically LTC4. Examination of edema formation and changes in vascular permeability in response to LTC4 suggests that the ability of mice to respond to LTC4 is at least one of the factors underlying strain differences in these models of inflammation. However, these results do not exclude the possibility that differences in cysteinyl-LT biosynthesis also exist in mouse strains that respond poorly to LTC4. It is also possible that differences in the production of and/or response to LTB4 may contribute to the strain variation seen in the 5LO-dependent component of inflammatory responses. In humans, it has been suggested that increased production of cysteinyl-LT correlates with susceptibility to aspirin-intolerant asthma (37, 38). Recent studies have shown that variations in the synthesis of cysteinyl-LT result from a polymorphism in the LTC4 synthase gene promoter, which causes constitutive overexpression of this enzyme in aspirin-sensitive patients (37, 38, 39, 40). Differing expression levels of LTC4 synthase may account for variability observed in the response to LT inhibitors used in the treatment of asthma (37).

The molecular basis for this differential response to LTC4 is not clear. The responses of these mouse lines to another acute inflammatory stimulus did not differ, suggesting that the interstrain variability is not the result of anatomical or physiological differences. The simplest explanation is that a decrease in the expression of the receptor on specific populations of cells within the responding tissue alters the inflammatory response. In addition, genetic polymorphisms in the structure of the LTC4 receptor may alter the binding of LTC4 to this receptor and/or the activation of signal transduction pathways associated with this receptor. Alternatively, LTC4 may be more rapidly metabolized in these tissues, and thereby reduce the effective dose. This latter explanation seems less likely given the high concentrations injected into the tissue and the acute nature of the response. With the cloning of the LTC4 receptor gene, it should be possible to address some of these questions specifically in the future.

In summary, we have examined the effect of genetic background on acute inflammatory responses in several genetically distinct strains of mice: 129, B6, and DBA. We demonstrated that the intensity of responses to specific inflammatory stimuli varies among these three strains, in the presence and absence of 5LO activity. The relative contributions of LT and prostanoids to each of these inflammatory models appear to be dependent upon other undefined genetic factors, which vary among these strains. It is also apparent that careful consideration is required in choosing strains to use for immunological studies because of the natural variation among inbred strains in responsiveness to stimuli and disease susceptibility. Future studies, similar to those described here, designed to study the effect of specific gene mutations on the natural phenotypes of different mouse strains will help us to better understand the interactions and roles of genetic factors in directing the course of immune responses in vivo.


    Acknowledgments
 
We thank M. Wade and S. Tilley for their critical review of this manuscript and T. Coffman for his helpful discussions. We also thank J. B. Garges, B. Hawkins, E. Hicks, and T. Mason for assistance with the animal husbandry and genotyping of the 5lo mice.


    Footnotes
 
1 This work was supported by National Institutes of Health Grant PO1-DK38108 and by Duke Training Grant in Nephrology 5-T32-DK07731. Back

2 Address correspondence and reprint requests to Dr. Beverly H. Koller, Department of Medicine, University of North Carolina, 7007 Thurston-Bowles Building, Chapel Hill, NC 27599-7248. Back

3 Abbreviations used in this paper: LT, leukotriene; 5LO, 5-lipoxygenase; AA, arachidonic acid; B6, C57BL/6; BK, bradykinin; COX, cyclooxygenase; DBA, DBA/1Lac; ES, embryonic stem; INDO, indomethacin; PL, phospholipase; s, secretory. Back

Received for publication September 9, 1999. Accepted for publication February 17, 2000.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Needleman, P., J. Turk, B. A. Jakschik, A. R. Morrison, J. B. Lefkowith. 1986. Arachidonic acid metabolism. Annu. Rev. Biochem. 55:69.[Medline]
  2. Williams, K. I., G. A. Higgs. 1988. Eicosanoids and inflammation. J. Pathol. 156:101.[Medline]
  3. Goetzl, E. J., A. Songzhu, W. L. Smith. 1995. Specificity of expression and effects of eicosanoid mediators in normal physiology an human diseases. FASEB J. 9:1051.[Abstract]
  4. Smith, W. L.. 1992. Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol. 263:F181.[Abstract/Free Full Text]
  5. Kudo, I., M. Murakami, S. Hara, K. Inoue. 1993. Mammalian non-pancreatic phospholipases A2. Biochim. Biophys. Acta. 117:217.
  6. Mukherjee, A. B., L. Miele, N. Pattabiraman. 1994. Phospholipase A2 enzymes: regulation and physiological role. Biochem. Pharmacol. 48:1.[Medline]
  7. Peters-Golden, M., R. W. McNish. 1993. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem. Biophys. Res. Commun. 196:147.[Medline]
  8. Woods, J. W., J. F. Evans, D. Ethier, S. Scott, P. J. Vickers, L. Hearn, J. A. Heibein, S. Charleson, I. I. Singer. 1993. 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J. Exp. Med. 178:1935.[Abstract/Free Full Text]
  9. Ford-Hutchinson, A. W., M. Gresser, R. N. Young. 1994. 5-Lipoxygenase. Annu. Rev. Biochem. 63:383.[Medline]
  10. Woods, J. W., M. J. Coffey, T. G. Brock, I. I. Singer, M. Peters-Golden. 1995. 5-Lipoxygenase is located in the euchromatin of the nucleus in the resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J. Clin. Invest. 95:2035.
  11. Samuelsson, B.. 1983. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220:568.[Abstract/Free Full Text]
  12. Jr Henderson, W. R.. 1994. The role of leukotrienes in inflammation. Ann. Intern. Med. 121:684.[Abstract/Free Full Text]
  13. Lewis, R. A., K. F. Austen, R. J. Soberman. 1990. Leukotrienes and other products of the 5-lipoxygenase pathway, biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323:645.[Medline]
  14. Goetzl, E. J., W. C. Pickett. 1980. The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs). J. Immunol. 125:1789.[Abstract]
  15. Smith, M. J. H., A. W. Ford-Hutchinson, M. A. Bray. 1980. Leukotriene B4: a potential mediator of inflammation. J. Pharm. Pharmacol. 32:517.[Medline]
  16. Pettipher, E. R., E. D. Salter, R. Breslow, L. Raycroft, H. J. Showell. 1993. Specific inhibition of leukotriene B4 (LTB4)-induced neutrophil emigration by 20-hydroxy LTB4: implications for the regulation of inflammatory responses. Br. J. Pharmacol. 110:423.[Medline]
  17. Dahlen, S.-E., J. Bjork, P. Hedqvist, K.-E. Arfors, S. Hammarstrom, J.-A. Lindgren, B. Samuelsson. 1981. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci. USA 78:3887.[Abstract/Free Full Text]
  18. Yokomizo, T., T. Izumi, K. Chang, T. Shimizu. 1997. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387:620.[Medline]
  19. Coleman, R. A., R. M. Eglen, R. L. Jones, S. Narumiya, T. Shimizu, W. L. Smith, S. E. Dahlen, J. M. Drazen, P. J. Gardiner, W. T. Jackson, et al 1995. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv. Prostaglandin Thromboxane Leukotriene Res. 23:283.[Medline]
  20. Metters, K. M.. 1995. Leukotriene receptors. J. Lipid Media. Cell Signal. 12:413.
  21. Lynch, K. R., G. P. O’Neill, Q. Liu, D.-S. Im, N. Sawyer, K. M. Metters, N. Coulombe, M. Abramovitz, D. J. Figueroa, Z. Zeng, et al 1999. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399:789.[Medline]
  22. Chen, X.-S., J. R. Sheller, E. N. Johnson, C. D. Funk. 1994. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372:179.[Medline]
  23. Goulet, J. L., J. N. Snouwaert, A. M. Latour, T. M. Coffman, B. H. Koller. 1994. Altered inflammatory responses in leukotriene-deficient mice. Proc. Natl. Acad. Sci. USA 91:12852.[Abstract/Free Full Text]
  24. Byrum, R. S., J. L. Goulet, R. J. Griffiths, B. H. Koller. 1997. Role of the 5-lipoxygenase activating protein (FLAP) in murine acute inflammatory responses. J. Exp. Med. 185:1065.[Abstract/Free Full Text]
  25. Goulet, J. L., R. C. Griffiths, P. Ruiz, R. F. Spurney, D. S. Pisetsky, B. H. Koller, T. M. Coffman. 1999. Deficiency of 5-lipoxygenase abolishes sex-related survival differences in MRL-lpr/lpr mice. J. Immunol. 163:359.[Abstract/Free Full Text]
  26. De Sanctis, G. T., J. M. Drazen. 1997. Genetics of native airway responsiveness in mice. Am. J. Respir. Crit. Care Med. 156:S82.[Abstract/Free Full Text]
  27. Kennedy, B. P., P. Payette, J. Mudgett, P. Vadas, W. Pruzanski, M. Kwan, C. Tang, D. E. Rancourt, W. A. Cromlish. 1995. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 270:22378.[Abstract/Free Full Text]
  28. MacPhee, M., K. P. Chepenik, R. A. Liddell, K. K. Nelson, L. D. Siracusa, A. M. Buchberg. 1995. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81:957.[Medline]
  29. Jancso-Gabor, A., J. Szolcsanyi, N. Jancso. 1967. A simple method for measuring the amount of azovan blue exuded into the skin in response to an inflammatory stimulus. J. Pharm. Pharmacol. 19:486.[Medline]
  30. Rao, T. S., J. L. Currie, A. F. Shaffer, P. C. Isakson. 1994. In vivo characterization of zymosan-induced mouse peritoneal inflammation. J. Pharmacol. Exp. Ther. 269:917.[Abstract/Free Full Text]
  31. Hooper, M., K. Hardy, A. Handyside, S. Hunter, M. Monk. 1987. HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 326:292.[Medline]
  32. Young, J. M., D. A. Spires, C. J. Bedord, B. Wagner, S. J. Ballaron, L. M. De Young. 1984. The mouse ear inflammatory response to topical arachidonic acid. J. Invest. Dermatol. 82:367.[Medline]
  33. Carlson, R. P., L. O’Neill-Davis, J. Chang, A. J. Lewis. 1985. Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents. Agents Actions 17:197.[Medline]
  34. Opas, E. E., R. J. Bonney, J. L. Humes. 1985. Prostaglandin and leukotriene synthesis in mouse ears inflamed by arachidonic acid. J. Invest. Dermatol. 84:253.[Medline]
  35. Chang, J., R. P. Carlson, L. O’Neill-Davis, B. Lamb, R. N. Sharma, A. J. Lewis. 1986. Correlation between mouse skin inflammation induced by arachidonic acid and eicosanoid synthesis. Inflammation 10:205.[Medline]
  36. Langenbach, R., S. G. Morham, H. F. Tiano, C. D. Loftin, B. I. Ghanayem, P. C. Chulada, J. F. Mahler, C. A. Lee, E. H. Goulding, K. D. Kluckman, et al 1995. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483.[Medline]
  37. Claesson, H.-E., S.-E. Dahlen. 1999. Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. J. Intern. Med. 245:205.[Medline]
  38. Sanak, M., A. P. Sampson. 1999. Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma. Clin. Exp. Allergy 29:306.[Medline]
  39. Sanak, M., H.-U. Simon, A. Szczeklik. 1997. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 350:1599.[Medline]
  40. Cowburn, A. S., K. Sladek, J. Soja, L. Adamek, E. Nizankowska, A. Szczeklik, B. K. Lam, J. F. Penrose, K. F. Austen, S. T. Holgate, A. P. Sampson. 1998. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 101:834.[Medline]



This article has been cited by other articles:


Home page
FASEB J.Home page
K. Wada, M. Arita, A. Nakajima, K. Katayama, C. Kudo, Y. Kamisaki, and C. N. Serhan
Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation
FASEB J, September 1, 2006; 20(11): 1785 - 1792.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Nguyen, A. J. Pace, and B. H. Koller
Age-Induced Reprogramming of Mast Cell Degranulation
J. Immunol., November 1, 2005; 175(9): 5701 - 5707.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
P. Caironi, F. Ichinose, R. Liu, R. C. Jones, K. D. Bloch, and W. M. Zapol
5-Lipoxygenase Deficiency Prevents Respiratory Failure during Ventilator-induced Lung Injury
Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 334 - 343.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
H. Hakonarson, S. Thorvaldsson, A. Helgadottir, D. Gudbjartsson, F. Zink, M. Andresdottir, A. Manolescu, D. O. Arnar, K. Andersen, A. Sigurdsson, et al.
Effects of a 5-Lipoxygenase-Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction: A Randomized Trial
JAMA, May 11, 2005; 293(18): 2245 - 2256.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. E. Trebino, J. D. Eskra, T. S. Wachtmann, J. R. Perez, T. J. Carty, and L. P. Audoly
Redirection of Eicosanoid Metabolism in mPGES-1-deficient Macrophages
J. Biol. Chem., April 29, 2005; 280(17): 16579 - 16585.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Ogasawara, S. Ishii, T. Yokomizo, T. Kakinuma, M. Komine, K. Tamaki, T. Shimizu, and T. Izumi
Characterization of Mouse Cysteinyl Leukotriene Receptors mCysLT1 and mCysLT2. DIFFERENTIAL PHARMACOLOGICAL PROPERTIES AND TISSUE DISTRIBUTION
J. Biol. Chem., May 17, 2002; 277(21): 18763 - 18768.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. J. Aiello, P.-A. Bourassa, S. Lindsey, W. Weng, A. Freeman, and H. J. Showell
Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells in Mice
Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 443 - 449.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. L. Goulet, R. C. Griffiths, P. Ruiz, R. B. Mannon, P. Flannery, J. L. Platt, B. H. Koller, and T. M. Coffman
Deficiency of 5-Lipoxygenase Accelerates Renal Allograft Rejection in Mice
J. Immunol., December 1, 2001; 167(11): 6631 - 6636.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Z.-Z. Shi, B. Han, G. M. Habib, M. M. Matzuk, and M. W. Lieberman
Disruption of {gamma}-Glutamyl Leukotrienase Results in Disruption of Leukotriene D4 Synthesis In Vivo and Attenuation of the Acute Inflammatory Response
Mol. Cell. Biol., August 15, 2001; 21(16): 5389 - 5395.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
X. Chen and C. S. Yang
Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention
Carcinogenesis, August 1, 2001; 22(8): 1119 - 1129.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. Ichinose, W. M. Zapol, A. Sapirstein, R. Ullrich, A. M. Tager, K. Coggins, R. Jones, and K. D. Bloch
Attenuation of Hypoxic Pulmonary Vasoconstriction by Endotoxemia Requires 5-Lipoxygenase in Mice
Circ. Res., April 27, 2001; 88(8): 832 - 838.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goulet, J. L.
Right arrow Articles by Koller, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goulet, J. L.
Right arrow Articles by Koller, B. H.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*INDOMETHACIN


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS